Danaher Corporation $DHR Position Reduced by MetLife Investment Management LLC

Key Points

• MetLife Investment Management LLC has decreased its stake in Danaher Corporation by 2.3%, now holding 166,329 shares valued at approximately $34 million.
• Various hedge funds have shown significant interest in Danaher, with Nuveen LLC investing over $833 million and other firms increasing their holdings substantially in the first quarter.
• Danaher recently reported earnings of $1.80 per share for the last quarter, exceeding expectations, and has set a fiscal year 2025 EPS guidance of between $7.700 and $7.800.

MetLife Investment Management LLC lessened its stake in Danaher Corporation (NYSE:DHR - Free Report) by 2.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 166,329 shares of the conglomerate's stock after selling 3,864 shares during the quarter. MetLife Investment Management LLC's holdings in Danaher were worth $34,097,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. GHP Investment Advisors Inc. increased its holdings in shares of Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares in the last quarter. Heck Capital Advisors LLC acquired a new stake in Danaher in the 4th quarter valued at about $27,000. Sierra Ocean LLC grew its stake in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after acquiring an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in Danaher in the 1st quarter valued at about $31,000. Finally, Dunhill Financial LLC grew its stake in Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after acquiring an additional 67 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Stock Up 0.2%

Shares of NYSE:DHR traded up $0.42 during midday trading on Thursday, reaching $205.42. The company had a trading volume of 2,519,753 shares, compared to its average volume of 4,185,368. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock's fifty day moving average price is $201.23 and its 200-day moving average price is $199.46. The stock has a market capitalization of $147.09 billion, a P/E ratio of 43.71, a PEG ratio of 2.88 and a beta of 0.73. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company's quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 11.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on DHR. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a report on Friday, July 11th. UBS Group lowered their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Evercore ISI decreased their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Robert W. Baird raised their target price on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research report on Friday, July 18th. Finally, Barclays reissued an "overweight" rating and issued a $225.00 target price (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.